Suchergebnisse - "33E86K87QN"

PubPharm (997)

1

Characterization of BRAFThr599dup Mutation as a Targetable Driver Mutation Identified in Lung Adenocarcinoma by Comprehensive Genomic Profiling

enthalten in: JCO precision oncology | 2024

von Watanabe, H. | Inoue, Y. | Karayama, M. | +11

2

Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

enthalten in: Molecular cancer | 2024

von Puyalto, A. | Rodríguez-Remírez, M. | López, I. | +14

3

Exceptionally long-lasting response to dabrafenib plus trametinib treatment in a patient with lung adenocarcinoma harboring the BRAF V600E mutation with high expression of PD-L1 : A case report

enthalten in: Thoracic cancer | 2024

von Inoue, T. | Kunimasa, K. | Tamiya, M. | +3

4

Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders

enthalten in: Haematologica | 2024

von Cournoyer, E. | Ferrell, J. | Sharp, S. | +11

5

Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma : a non-interventional, multicenter, prospective trial

enthalten in: Melanoma research | 2024

von Richtig, E. | Nguyen, V. | Koelblinger, P. | +19

6

The safety and efficacy of dabrafenib and trametinib in patients with glioma : A systematic review and meta-analysis

enthalten in: European journal of clinical pharmacology | 2024

von Habibi, M. | Mirjani, M. | Ahmadvand, M. | +2

7

Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma

enthalten in: Melanoma research | 2024

von Hennemann, A. | Puzenat, E. | Decreuse, M. | +3

8

Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma

enthalten in: Thyroid : official journal of the American Thyroid Association | 2024

von Hamidi, S. | Iyer, P. | Dadu, R. | +6

9

Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation : A First in Non-Small Cell Lung Cancer

enthalten in: Journal of the National Comprehensive Cancer Network : JNCCN | 2024

von Sharp, J. | Jones, D. | Rotow, J. | +3

10

Ultrasound-propelled liposome circumvention and siRNA silencing reverse BRAF mutation-arised cancer resistance to trametinib

enthalten in: Colloids and surfaces. B, Biointerfaces | 2024

von Chen, J. | Fang, C. | Chang, C. | +7

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[100]